Axsome Therapeutics, Inc. 8-K Report: Key Insights from December 30, 2024 Filing

Based on the provided section of the financial report, here are the extracted key pieces of information:

Entity Information:

Company Name: Axsome Therapeutics, Inc.
CIK: 0001579428
SEC File Number: 001-37635
EIN: 45-4241907
Address: One World Trade Center, 22nd Floor, New York, NY 10007
Contact Number: (212) 332-3241

Document Type:

Filing Type: 8-K (Current Report)
Filing Date: December 30, 2024

Stock Information:

Stock Ticker Symbol: AXSM
Exchange: NASDAQ
Common Stock Par Value: $0.0001 per share

Reporting Period:

Start Date: December 30, 2024
End Date: December 30, 2024

Insights:

The filing is an 8-K, which typically reports significant events that shareholders should know about. This could indicate that there was a noteworthy occurrence within the company on the reporting date.
Axsome Therapeutics, Inc. is a publicly traded company on NASDAQ, which suggests it is subject to rigorous reporting standards and regulatory scrutiny.
The report indicates that the financial disclosures are made in accordance with the XBRL format, which is designed to improve the transparency and accessibility of financial data.

This analysis provides a snapshot of the company's current reporting status and essential corporate information that could be relevant for investors and analysts reviewing the company's financial health and market position.